Publication: The reality of using primaquine
Issued Date
2010-12-29
Resource Type
ISSN
14752875
Other identifier(s)
2-s2.0-78650438094
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Malaria Journal. Vol.9, No.1 (2010)
Suggested Citation
Kathy L. Burgoine, Germana Bancone, François Nosten The reality of using primaquine. Malaria Journal. Vol.9, No.1 (2010). doi:10.1186/1475-2875-9-376 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/29149
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The reality of using primaquine
Author(s)
Abstract
Background: Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased susceptibility to haemolysis when given primaquine. This potentially fatal clinical syndrome can be avoided if patients are tested for G6PD deficiency and adequately informed before being treated. Case presentation. A 35-year old male presented to our clinic on the Thai-Burmese border with a history and clinical examination consistent with intravascular haemolysis. The patient had been prescribed primaquine and chloroquine four days earlier for a P. vivax infection. The medication instructions had not been given in a language understood by the patient and he had not been tested for G6PD deficiency. The patient was not only G6PD deficient but misunderstood the instructions and took all his primaquine tablets together. With appropriate treatment the patient recovered and was discharged home a week later. Conclusions. Whilst primaquine remains the drug of choice to eradicate hypnozoites and control P. vivax transmission, the risks associated with its use must be minimized during its deployment. In areas where P. vivax exists, patients should be tested for G6PD deficiency and adequately informed before administration of primaquine. © 2010 Burgoine et al; licensee BioMed Central Ltd.